Case Report: Severe hypertriglyceridaemia and multivessel coronary artery disease - management and plaque characteristics
Abstract
Background: Elevated triglycerides have been established as a cardiovascular risk marker and the literature suggests an association with lipid-rich plaques. We report a case of severe hypertriglyceridaemia that did not result in lipid-rich atherosclerotic lesions.
Case summary: Coronary angiography of a 54-year-old man with a triglyceride level >113.00 mmol/L revealed severe multivessel disease. Near-infrared spectroscopy (NIRS) demonstrated a low plaque lipid content, including the maximum lipid-core burden index within 4 mm of 0 in the right coronary artery (RCA), with >90% stenosis in the middle segment. To achieve a rapid reduction in the triglyceride level, intravenous administration of insulin and heparin combined with subsequent plasmapheresis was used, and a triglyceride level of 5.79 mmol/L was achieved before discharge. Genetic testing confirmed familial hypertriglyceridaemia with a pathogenic variant in the lipoprotein lipase gene.
Conclusions: In a patient with severely elevated serum triglycerides and premature three-artery disease, low plaque lipid content was established with the NIRS investigation. Pharmacological management of very severe hypertriglyceridaemia with intravenous insulin and heparin therapy can rapidly decrease triglyceride levels.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.